Environmentally induced autoimmune diseases: Potential mechanisms

Environmental Health Perspectives

Volumn 107, Issue SUPPL. 5, 1999, Pages 737-742

  Rao, Tharaknath ^a   Richardson, Bruce ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c Geriatrics Center   (United States)

Author keywords

Anergy; Autoimmunity; Deletion; Mechanisms; Suppression; Tolerance; Xenobiotic

Indexed keywords

ALIMEMAZINE; BUTYRIC ACID; CYCLOSPORIN A; CYTARABINE; CYTOKINE; ESTROGEN; GAMMA INTERFERON; GOLD SALT; HAPTEN; HYDRALAZINE; PHYTOESTROGEN; PROCAINAMIDE; RESVERATROL; TRANSFORMING GROWTH FACTOR BETA; TRICHOSTATIN A; XENOBIOTIC AGENT;

ANTIGEN RECOGNITION; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHROMATIN STRUCTURE; CLONAL ANERGY; ENVIRONMENT; GENE DELETION; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE FUNCTION; NONHUMAN; PRIORITY JOURNAL;

ANIMALIA;

EID: 0032729725     PISSN: 00916765     EISSN: None     Source Type: Journal    
DOI: 10.1289/ehp.99107s5737     Document Type: Article

References (89)

1. Yung RL, Richardson BC. Drug-induced lupus. Rheum Dis Clin North Am 20:61-86 (1994).
2. Philen RM, Posada de la Paz M, Hill RH, Schurz HH, Abaitua-Borda I, Gomez de la Camara A, Kilbourne EM. Epidemiology of the toxic oil syndrome. Arch Toxicol 19:41-52 (1997).
3. Gomez de la Camara A, Abaitua-Borda I, Posada de la Paz M. Toxicologists versus toxicological disasters: toxic oil syndrome, clinical aspects. Arch Toxicol 19:31-40 (1997).
4. Belongia EA, Hedberg CW, Gleich GJ, White KE, Mayeno AN, Loegering DA, Dunnette SL, Pirie PL, MacDonald KL, Osterholm MT. An investigation into the cause of the eosinophilia-myalgia syndrome associated with tryptophan use. Eng J Med 323:357-365 (1990).
5. Kaufman LD, Gleich GJ. Eosinophilia myalgia syndrome. In: Rheumatic Diseases and the Environment (Kaufman LD, Varga J, eds). London:Arnold, 1999:55-73.
6. Goodnow CC. Balancing immunity and tolerance: deleting and tuning lymphocyte repertoires. Proc Natl Acad Sci USA 93:2264-2271 (1996).
7. Mondino A, Khoruts A, Jenkins MK. The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci USA 93:2245-2252 (1996).
8. Kronenberg M. Self-tolerance and autoimmunity. Cell 65:537-542 (1991).
9. Schwartz RH. Models of T cell anergy: is there a common molecular mechanism? J Exp Med 184:1-8 (1996).
10. Beverly B, Kang SM, Lenardo MJ, Schwartz RH. Reversal of in vitro T cell clonal anergy by IL-2 stimulation. Int Immunol 4:661-671 (1992).
11. Watanabe-Fukunaga R, Brannan CI, Copeland NG, Jenkins NA, Nagata S. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. Nature 356:314-317 (1992).
12. Nagata S, Suda T. Fas and Fas ligand: lpr and gld mutations. Immunol Today 16:39-43 (1995).
13. Wu J, Zhou T, Zhang J, He J, Gause WC, Mountz JD. Correction of accelerated autoimmune disease by early replacement of the mutated ipr gene with the normal Fas apoptosis gene in the T cells of transgenic MRL-lpr/lpr mice. Proc Natl Acad Sci USA 91:2344-2348 (1994).
14. Straus SE, Sneller M, Lenardo MJ, Puck JM, Strober W. An inherited disorder of lymphocyte apoptosis: the autoimmune lymphoproliferative syndrome. Ann Intern Med 130:591-601 (1999).
15. DeFranco AL. Immunosuppressants at work. Nature 352:754-755 (1991).
16. Bucy RP, Xu XY, Li J, Huang GQ. Cyclosporin A-induced autoimmune disease in mice. J Immunol 151:1039-1050 (1993).
17. Sakaguchi N, Miyai K, Sakaguchi S. Ionizing radiation and autoimmunity. J Immunol 152:2586-2595 (1994).
18. Bonomo A, Kehn PJ, Payer E, Rizzo L, Cheever AW, Shevach EM. Pathogenesis of post-thymectomy autoimmunity. J Immunol 154:6602-6611 (1995).
19. Moreb JS, Kubilis PS, Mullins DL, Myers L, Youngblood M, Hutcheson C. Increased frequency of autoaggression syndrome associated with autologous stem cell transplantation in breast cancer patients. Bone Marrow Transplant 19(2):101-106 (1997).
20. Kretz-Rommel A, Duncan SR, Rubin RL. Autoimmunity caused by disruption of central T cell tolerance. J Clin Invest 99:1888-1896 (1997).
21. Kretz-Rommel A, Rubin RL. A metabolite of the lupus-inducing drug procainamide prevents anergy induction in T-cell clones. J Immunol 158:4465-4470 (1997).
22. Doerfler, W. DNA Methylation and gene activity. Annu Rev Biochem 52:93-124 (1983).
23. Nan X, Ng HH, Johnson CA, Laherty CD, Turner BM, Eisenman RN, Bird A. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 393:386-389 (1998).
24. Bestor T, Laudano A, Mattaliano R, Ingram V. Cloning and sequencing of a cDNA encoding DNA methyltansferase of mouse cells The carboxy-terminal domain of the mammalian enzymes is related to bacterial restriction of methyltransferases. J Mol Biol 203:971-963 (1988).
25. Richardson BC, Strahler JR, Pivirotto TS, Quddus J, Bayliss GE, Gross LA, O'Rourke KS, Powers DJ, Hanash SM, Johnson MA. Phenotypic and functional similarities between 5-azacytidine treated T cells and a T-cell subset in patients with active systemic lupus erythematosus. Arthritis Rheum 35:647-662 (1992).
26. Richardson BC, Powers D, Hooper F, Yung RL, O'Rourke K. Lymphocyte function-associated antigen 1 overexpression and T cell autoreactivity. Arthritis Rheum 37:1363-1372 (1994).
27. Yung R, Powers D, Johnson K, Amento E, Carr D, Laing T, Yang J, Chang S, Hemati N, Richardson B. Mechanisms of drug-induced lupus. II: T cells overexpressing lymphocyte function-associated antigen 1 become autoreactive and cause a lupuslike disease in syngeneic recipients. J Clin Invest 97:2866-2871 (1996).
28. Cornacchia E, Golbus J, Maybaum J, Strahler J, Hanash S, Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J Immunol 140:2197-2200 (1968).
29. Yung RL, Chang S, Hemati N, Johnson K, Richardson BC. Mechanisms of drug-induced lupus. IV: Comparison of procainamide and hydralazine with analogs in vitro and in vivo. Arthritis Rheum 40:1436-1443 (1997).
30. + T cells with either of two distinct DNA methyltransferase inhibitors, 5-azacytidine or procainamide, is sufficient to induce a lupus-like disease in syngeneic mice. J Clin Invest 92:38-53 (1993).
31. Yung RL, Quddus J, Chrisp CE, Johnson KJ, and Richardson BC. Mechanisms of Drug Induced Lupus. I: Cloned Th2 cells modified with DNA methylation inhibitors in vitro cause autoimmunity in vivo. J Immunol 154:3025-3035 (1995).
32. Richardson B, Scheinbart L, Strahler J, Gross L, Hanash S, Johnson M. Evidence for impaired T cell DNA methylation in systemic lupus erythematosus and rheumatoid arthritis. Arthritis Rheum 33:1665-1673 (1990).
33. Pazin MJ, Kadonaga JT. What's up and down with histone deacetylation and transcription? Cell 89:325-328 (1997).
34. Bird JJ, Brown DR, Mullen AC, Moskowitz NH, Mahowald MA, Sider JR, Gajewski TF, Wang CR, Reiner SL Helper T cell differentiation is controlled by the cell cycle. Immunity 9:229-237 (1998).
35. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 42:65-82 (1982).
36. Chen WY, Bailey EC, McCune SL, Dong JY, Townes TM. Reactivation of silenced, vitally transduced genes by inhibitors of histone deacetylase. Proc Natl Acad Sci USA 94:5798-5803 (1997).
37. Krieg AM, Steinberg AD. Analysis of thymic endogenous retroviral expression in murine lupus. J Clin Invest 86:809-816 (1990).
38. Zardo G, Marenzi S, Caiafa P. H1 histone as a trans-acting factor involved in protecting genomic DNA from full methylation. Biol Chem 379:647-654 (1998).
39. Zardo G, Caiafa P. The unmethylated state of CpG islands in mouse fibroblasts depends on the poly(ADP-ribosyl)ation process. J Biol Chem 273:16517-16520 (1998).
40. Yung RL, Richardson BC. Pathophysiology of drug-induced lupus. In: Systemic Lupus Erythematosus (Lahita RG, ed). New York:Academic Press, 1998:909-928.
41. Ayer LM, Edworthy SM, Fritzler MJ. Effect of procainamide and hydralazine on poly (ADP-ribosylation) in cell lines. Lupus 2:167-172 (1993).
42. Okamoto S, Azhipa O, Yu Y, Russo E, Dennert G. Expression of ADP-ribosyltransferase on normal T lymphocytes and effects of nicotinamide adenine dinucleotide on their function. J Immunol 160:4190-4198 (1998).
43. Tsao BP, Cantor RM, Grossman JM, Theophilov N, Wallace DJ, Arnett FC, Hartung K, Goldstein R, Kalunian KC, Hahn BH, et al. ADPRT alleles from the chromosome 1q41-q42 linked region are associated with SLE. Arthritis Rheum 41:S80 (1998)
44. Chen HY, Pertusi RM, Kirkland JB, Rubin BR, Jacobson EL. Biochemical characterization of ADP-ribose polymer metabolism in SLE. Lupus 5:14-21 (1996).
45. Lee JS, Haug BL, Sibley JT. Decreased mRNA levels coding for poly (ADP-ribose) polymerase in lymphocytes of patients with SLE. Lupus 3:113-116 (1994).
46. Da Silva JAP. Sex hormones, glucocorticoids and autoimmunity: facts and hypotheses. Ann Rheum Dis 54:6-16 (1995).
47. 1 mice. J Exp Med 147:1568-1583 (1978).
48. Ahmed SA, Dauphinee MJ, Talal N. Effects of short-term administration of sex hormones on normal and autoimmune mice. J Immunol 134:204-210 (1965).
49. Petri M, Robinson C. Oral contraceptives and systemic lupus erythematosus. Arthritis Rheum 40:797-803 (1997).
50. Cutolo M, Sulli A, Seriolo B, Accardo S, Masi AT. Estrogens, the immune response and autoimmunity. Clin Exp Rheumatol 13:217-226 (1995).
51. Rubanyi GM, Freay AD, Kauser K, Sukovich D, Burton G, Lubahn DB, Couse JF, Curtis SW, Korach KS. Vascular estrogen receptors and endothelium-derived nitric oxide production in the mouse aorta. J Clin Invest 99:2429-2437 (1997).
52. Yung RL, Williams RM, Johnson K, Stoolman L, Chang S, Richardson BC. Mechanisms of drug-induced lupus. III: Sex-specific differences in T cell homing may explain increased disease severity in female mice. Arthritis Rheum 40:1334-1343 (1997).
53. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 94:14138-14143 (1997).
54. Ortmann O, Sturm R, Knuppen R, Emons G. Weak estrogenic activity of phenol red in the pituitary gonadotroph: re-evaluation of estrogen and antiestrogen effects. J Steroid Biochem 35:17-22 (1990).
55. Zhang Z, Michael JG. Orally inducible immune unresponsiveness is abrogated by IFN-γ treatment. J Immunol 144:4163-4165 (1990).
56. Gianani R, Sarvetnick N. Viruses, cytokines, antigens, and autoimmunity. Proc Natl Acad Sci USA 93:2257-2259 (1996).
57. Takorabet L, Ropars A, Raby C, Charreire J. Phenothiazine induces de novo MHC Class II antigen expression on thyroid epithelial cells. J Immunol 154:3593-3602 (1995).
58. Koeger AC, Lang T, Alcaix D, Milleron B, Rozenberg S, Chaibi P, Arnaud J, Wayaud C, Camus JP, Bourgeois P. Silica-associated connective tissue disease. Medicine 74:221-237 (1995).
59. Cooper GS. Dooley MA, Treadwell EL, St. Clair EW, Parks CG, Gilkeson GS. Hormonal, environmental, and infectious risk factors for developing systemic lupus erythematosus. Arthritis Rheum 41:1714-1724 (1998).
60. Shull MM, Orrnsby I, Kier AB, Pawlowski S, Diebold RJ, Yin M, Allen R, Sidman C, Proetzel G, Calvin D, et al. Targeted disruption of the mouse transforming growth factor-β1 gene results in multifocal inflammatory disease. Nature 359:693-699 (1992).
61. Wahl SM. Transforming growth factor β: the good, the bad, and the ugly. J Exp Med 180:1587-1590 (1994).
62. Chen JJ, Yongnian S, Nabel GJ. Regulation of the proinflammatory effects of Fas ligand (CD95L). Science 282:1714-1717 (1998).
63. Street NE, Mosmann TP. Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 5:171-177 (1991).
64. Miossec P, Vandenberg WIM. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 40:2105-2115 (1997).
65. Bird JJ, Brown DR, Mullen AC, Moskowitz NH, Mahowald MA, Sider JR, Gajewski TF, Wang C, Reiner SI. Helper T Cell differentiation is controlled by the cell cycle. Immunity 9:229-237 (1998).
66. Apte RS, Sinha D, Mayhew E, Wistow GJ, Niedarkorn JY. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J Immunol 160:5693-5696 (1998).
67. Jacob CO, McDevitt HO. Tumour necrosis factor-α in murine autoimmune 'lupus' nephritis. Nature 331:356-358 (1988).
68. Maini RN, Elliott MJ, Charles PJ, Feldmann M. Immunological intervention reveals reciprocal roles for tumor necrosis factor-α and interleukin-10 in rheumatoid arthritis and systemic lupus erythematosus. Springer Semin Immunopathol 16:327-336 (1994).
69. Alessi DR, Cuenda A, Cohen P, Dudley DT, Saltiel AR. PD 098059 is a specific inhibitor of the activation of mitogen-activaled protein kinase in vitro and in vivo. J Biol Chem 270:27489-27494 (1995).
70. Deng C, Yang J, Scott J, Hanash S, Richardson B. Role of the ras-MAPK signaling pathway in the DNA methyltransferase response to DNA hypomethylation. Biol Chem 379:1113-1120 (1998).
71. Salas VM, Burchiel SW. Apoptosis in daudi human B cells in response to benzo[a]pyrene and benzo[a]pyrene-7,B-dihydrodiol. Toxicol Appl Pharmacol 151(2):367-376 (1998).
72. Tannheimer SL, Ethier SP, Caldwell KK, Burchiel SW. Benzo[a]pyrene-and TCDD-induced alterations in tyrosine phosphorylation and insulin-like growth factor signaling pathways in the MCF-10A human mammary epithelial cell line. Carcinogenesis 19(7):1291-1297 (1998).
73. Casciola-Rosen LA, Anhalt G, Rosen A. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes. J Exp Med 179:1317-1330 (1994).
74. Tan EM. Autoimmunity and apoptosis. J Exp Med 179:1083-1086 (1994).
75. Gottesfeld JM, Neely L, Trauger JW, Baird EE, Dervan PB. Regulation of gene expression by small molecules. Nature 387:202-205 (1997).
76. Griem P, Wulferink M, Sachs B, Gonzàlez JB, Gleichmann E. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today 19:133-141 (1938).
77. Craft J, Fatenejad S. Self antigens and epitope spreading in systemic autoimmunity. Arthritis Rheum 40:1374-1382 (1997).
78. James JA, Gross T, Scofield RH, Harley JB. Immunoglobulin epitope spreading and autoimmune disease after peptide immunization: Sm B/B′-derived PPPGMRPP and PPPGIRGP induce spliceosome autoimmunity. J Exp Med 181:453-451 (1995).
79. Reuter R, Tessars G, Vohr HW, Gleichmann E, Lührmann R. Mercuric chloride induces autoantibodies against U3 small nuclear ribonucleoprotein in susceptible mice. Proc Natl Acad Sci USA 86:237-241 (1989).
80. Pollard KM, Lee DK, Casiano CA, Blüthner M, Johnston M, Tan EM. The autoimmunity-inducing xenobiotic mercury interacts with the autoantigen fibrillarin and modifies its molecular and antigenic properties. J Immunol 158:3521-3528 (1997).
81. Thomas TJ, Messner RP. Effects of lupus-inducing drugs on the B to Z transition of synthetic DNA. Arthritis Rheum 29:638-643 (1986).
82. Gleichmann H. Studies on the mechanism of drug sensitization: T-cell dependent popliteal lymph node reaction to diphenylhydantoin. Clin Immunol Immunopathol 18:203-211 (1981).
83. Gleichmann E, Pals ST, Rolink AG, Radaszkiewicz T, Gleichmann H. Graft-versus-host reactions: clues to the etiopathology of a spectrum of immunological diseases. Immunol Today 5:324-332 (1984).
84. Ward A, Udnoon S, Watkins J, Walker AE, Darke CS. Immunological mechanisms in the pathogenesis of vinyl chloride disease. Br Med J 1:936-938 (1976).
85. Lanzavecchia A. How can cryptic epitopes trigger autoimmunity? J Exp Med 181:1945-1948 (1995).
86. Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: implications for pathogenesis. J Exp Med 185:71-79 (1997).
87. Theofilopoulos AN. The basis of autoimmunity. Part I: Mechanisms of aberrant self-recognition. Immunol Today 16:90-98 (1995).
88. Schiffenbauer J, Soos J, Johnson H. The possible role of bacterial superantigens in the pathogenesis of autoimmune disorders. Immunol Today 19:117-120 (1998).
89. Singh RR, Kumar V, Ebling FM, Southwood S, Sette A, Sercarz EE, Hahn BH. T cell determinants from autoantibodies to DNA can upregulate autoimmunity in murine systemic lupus erythematosus. J Exp Med 181:2017-2027 (1995).